Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Sep 5;13(9):e0007605.
doi: 10.1371/journal.pntd.0007605. eCollection 2019 Sep.

The costs of monitoring trachoma elimination: Impact, surveillance, and trachomatous trichiasis (TT)-only surveys

Affiliations
Review

The costs of monitoring trachoma elimination: Impact, surveillance, and trachomatous trichiasis (TT)-only surveys

Rachel D Stelmach et al. PLoS Negl Trop Dis. .

Abstract

Background: Although trachoma causes more cases of preventable blindness than any other infectious disease, a combination of strategies is reducing its global prevalence. As a district moves toward eliminating trachoma as a public health problem, national programs conduct trachoma impact surveys (TIS) to assess whether to stop preventative interventions and trachoma surveillance surveys (TSS) to determine whether the prevalence of active trachoma has rebounded after interventions have halted. In some contexts, programs also conduct trachomatous trichiasis (TT)-only surveys. A few costing studies of trachoma prevalence surveys exist, but none examine TIS, TSS, or TT-only surveys.

Methodology/principal findings: We assessed the incremental financial cost to the national program of TIS, TSS, and TT-only surveys, which are standardized cluster-sampled prevalence surveys. We conducted a retrospective review of expenditures and grant disbursements for TIS and TSS in 322 evaluation units in 11 countries between 2011 and 2018. We also assessed the costs of three pilot and five standard TT-only surveys in four countries between 2017 and 2018. The median cost of TIS and TSS was $8,298 per evaluation unit [interquartile range (IQR): $6,532-$10,111, 2017 USD]. Based on a linear regression with bootstrapped confidence intervals, after controlling for country, costs per survey did not change significantly over time but did decline by $83 per survey implemented in a single round (95% CI: -$108 --$63). Of total costs, 80% went to survey fieldwork; of that, 58% went towards per diems and 38% towards travel. TT-only surveys cost a median of $9,707 (IQR: $8,537-$11,635); within a given country, they cost slightly more (106% [IQR: 94%-136%]) than TIS and TSS.

Conclusions/significance: The World Health Organization requires trachoma prevalence estimates for validating the elimination of trachoma as a public health problem. This study will help programs improve their planning as they assemble resources for that effort.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Number of TIS and TSS conducted per year.
Each bar shows the number of each type of survey conducted in each year. As each EU must conduct TIS before TSS, TSS began being conducted in 2014, 3 years after the first TIS in our study.
Fig 2
Fig 2. Number of TIS and TSS conducted in each country.
The size of the bubble centered on each country represents the number of TIS and TSS included in the study from each country. Figure created by authors using R package rworldmap [17].
Fig 3
Fig 3. TIS and TSS cost distributions.
The histogram displays the cost per TIS and TSS with bins $1,000 (2017 USD) wide. The boxplot, which shares its x axis with the histogram, further summarizes the data. The bar in the middle of the boxplot shows the median, and the edges of the box represent the interquartile range (IQR), or the 25th and 75th percentiles. The whiskers display the spread of the rest of the data, except for the outliers, defined as observations that fall more than 1.5 times the IQR away from the median, which appear as dots.

References

    1. Flaxman SR, Bourne RRA, Resnikoff S, Ackland P, Braithwaite T, Cicinelli MV, et al. Global causes of blindness and distance vision impairment 1990–2020: a systematic review and meta-analysis. Lancet Glob Health. 2017;5: e1221–e1234. 10.1016/S2214-109X(17)30393-5 - DOI - PubMed
    1. Sarah V, Adams AB, Jesudason T. Celebrating 20 years of progress: accelerating towards elimination. Community Eye Health. 2018;31: 73 - PMC - PubMed
    1. WHO. Validation of elimination of trachoma as a public health problem [Internet]. 2016 Jun. Report No.: WHO/HTM/NTD/2016.8. Available: http://www.who.int/trachoma/resources/who_htm_ntd_2016.8/en/
    1. Solomon AW, Pavluck AL, Courtright P, Aboe A, Adamu L, Alemayehu W, et al. The Global Trachoma Mapping Project: Methodology of a 34-Country Population-Based Study. Ophthalmic Epidemiol. 2015;22: 214–225. 10.3109/09286586.2015.1037401 - DOI - PMC - PubMed
    1. WHO Strategic and Technical Advisory Group on Neglected Tropical Diseases. Technical consultation on trachoma surveillance September 11–12, 2014, Task Force for Global Health, Decatur, USA: [Internet]. Geneva: WHO; 2015 Jul. Report No.: WHO/HTM/NTD/2015.02. Available: https://www.who.int/trachoma/resources/who_htm_ntd_2015.02/en/

Publication types